Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Molecular cancer therapeutics - 1 Sept 2013

Gadhikar Mayur A, Sciuto Maria Rita, Alves Marcus Vinicius Ortega, Pickering Curtis R, Osman Abdullah A, Neskey David M, Zhao Mei, Fitzgerald Alison L, Myers Jeffrey N, Frederick Mitchell J

Abstract excerpt

Despite the use of multimodality therapy using cisplatin to treat patients with advanced stage squamous cell carcinoma of the head and neck (HNSCC), there is an unacceptably high rate of treatment failure. TP53 is the most commonly mutated gene in HNSCC, and the impact of p53 mutation on response to cisplatin treatment is poorly understood. Here, we show unambiguously that wild-type TP53 (wtp53) is associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Senescence
Share to Checkpoint Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 2

Share to Cisplatin

Share to Head and Neck Neoplasms

Share to Mitosis

Share to Thiophenes

Source

Open in PubMed Open full text

Identifiers

PMID: 23839309
DOI: 10.1158/1535-7163.MCT-13-0157
PMCID: PMC3955083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.PMID 23839309Read ↗

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.Semantic proximity Read ↗

Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell deathSemantic proximity Read ↗

p53-Independent Regulation of p21Waf1/Cip1 Expression and Senescence by Chk2Semantic proximity Read ↗

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.Semantic proximity Read ↗

Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase InhibitionSemantic proximity Read ↗

COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent MechanismsSemantic proximity Read ↗

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.Semantic proximity Read ↗

CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 InhibitionSemantic proximity Read ↗

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.Semantic proximity Read ↗

p53-based therapeutics for head and neck squamous cell carcinoma.Semantic proximity Read ↗

Dual Induction of Apoptosis and Senescence in Cancer Cells by Chk2 Activation: Checkpoint Activation as a Strategy against CancerSemantic proximity Read ↗

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.